196 related articles for article (PubMed ID: 8030167)
1. Diagnostic problems of urine cytology on initial follow-up after intravesical immunotherapy with Calmette-Guérin bacillus for superficial bladder cancer.
Mack D; Frick J
Urol Int; 1994; 52(4):204-7. PubMed ID: 8030167
[TBL] [Abstract][Full Text] [Related]
2. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study.
Witjes JA; Fransen MP; van der Meijden AP; Doesburg WH; Debruyne FM
Urol Int; 1993; 51(2):67-72. PubMed ID: 8351757
[TBL] [Abstract][Full Text] [Related]
3. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
[TBL] [Abstract][Full Text] [Related]
4. Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ?
Haase RN; Harving N
Scand J Urol; 2015; 49(4):338-40. PubMed ID: 25660358
[No Abstract] [Full Text] [Related]
5. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
6. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
[TBL] [Abstract][Full Text] [Related]
7. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
8. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
[TBL] [Abstract][Full Text] [Related]
9. Cytological changes induced by intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer.
Takashi M; Schenck U; Koshikawa T; Nakashima N; Ohshima S
Urol Int; 2000; 64(2):74-81. PubMed ID: 10810268
[TBL] [Abstract][Full Text] [Related]
10. Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract.
Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Nishimura K; Takaha N; Takahara S; Okuyama A
Eur Urol; 2000 Dec; 38(6):701-4;discussion 705. PubMed ID: 11111187
[TBL] [Abstract][Full Text] [Related]
11. Urinary interleukins in patients receiving intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer.
Fleischmann JD; Toossi Z; Ellner JJ; Wentworth DB; Ratliff TL; Imbembo AL
Cancer; 1989 Oct; 64(7):1447-54. PubMed ID: 2789094
[TBL] [Abstract][Full Text] [Related]
12. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
[TBL] [Abstract][Full Text] [Related]
13. Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma.
D'Ancona CA; Netto Júnior NR; Claro JA; Ikari O
J Urol; 1991 Mar; 145(3):498-501. PubMed ID: 1997698
[TBL] [Abstract][Full Text] [Related]
14. Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: pattern of recurrence.
Schwalb MD; Herr HW; Sogani PC; Russo P; Sheinfeld J; Fair WR
J Urol; 1994 Aug; 152(2 Pt 1):382-7. PubMed ID: 8015076
[TBL] [Abstract][Full Text] [Related]
15. A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?
Pagano F; Bassi P; Milani C; Meneghini A; Maruzzi D; Garbeglio A
J Urol; 1991 Jul; 146(1):32-5. PubMed ID: 2056600
[TBL] [Abstract][Full Text] [Related]
16. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
Netto Júnior NR; Levi d'Ancona CA; Claro JF; Ilari O
Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850
[TBL] [Abstract][Full Text] [Related]
17. Intravesical therapy for superficial bladder cancer.
Malkowicz SB
Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
Sarosdy MF; Lamm DL
J Urol; 1989 Sep; 142(3):719-22. PubMed ID: 2769847
[TBL] [Abstract][Full Text] [Related]
19. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
[TBL] [Abstract][Full Text] [Related]
20. Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity.
Lam JS; Benson MC; O'Donnell MA; Sawczuk A; Gavazzi A; Wechsler MH; Sawczuk IS
Urol Oncol; 2003; 21(5):354-60. PubMed ID: 14670544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
